
Lyudmila Bazhenova, MD, discusses targeted therapies for patients with HER2-mutated non–small cell lung cancer.

Lyudmila Bazhenova, MD, discusses targeted therapies for patients with HER2-mutated non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with BRAF-mutated non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with MET-mutated non–small cell lung cancer.

Lyudmila Bazhenova, MD, discusses targeted therapies for patients with KRAS-mutated non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.






Lyudmila Bazhenova, MD, presents the case of a 58-year-old woman with ALK+ non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the prevalence of patients with non-driver non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the currently available treatment strategies for patients with non-driver non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses what potential impact immunotherapy agents could have on outcomes for patients with non-driver non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses ongoing and remaining challenges in the field of non-driver non–small cell lung cancer, as well as a look toward the future treatment landscape.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the prevalence of patients with non-driver non–small cell lung cancer.

Published: March 29th 2022 | Updated:

Published: September 8th 2020 | Updated:

Published: September 8th 2020 | Updated:

Published: September 8th 2020 | Updated:

Published: September 8th 2020 | Updated:

Published: September 8th 2020 | Updated: